venou
thromboembol
vte
includ
acut
pulmonari
embol
ape
chronic
thromboembol
pulmonari
hypertens
cteph
deep
venou
thrombosi
dvt
global
diseas
high
morbid
high
misdiagnosi
rate
high
mortal
render
pe
worldwid
health
egeberg
et
al
first
describ
parentag
inherit
antithrombin
defici
member
repeatedli
develop
dvt
antithrombin
defici
autosom
domin
genet
diseas
first
propos
concept
howev
evid
genet
pathogenesi
vte
rare
identifi
major
vte
patient
accord
pathogenesi
vte
classifi
genet
vte
acquir
vte
frequent
found
clinic
practic
symptomat
vte
entiti
hereditari
vte
acquir
vte
american
colleg
chest
physician
accp
recommend
guidelin
diagnosi
prevent
vte
sinc
total
issu
publish
end
content
also
continu
renew
accp
propos
trauma
surgeri
old
age
malign
pregnanc
heart
failur
oral
administr
contracept
main
risk
factor
vte
accp
also
propos
concept
risk
stratif
prophylaxi
vte
differ
manag
use
prevent
vte
differ
risk
incid
symptomat
vte
reduc
gradual
increas
reason
may
relat
unclear
pathogenesi
smeeth
et
al
report
occurr
vte
associ
infect
vte
frequent
observ
within
week
report
vte
multipl
organ
patient
die
sar
suggest
viral
infect
caus
system
addit
detect
viruslik
microorgan
lymphocyt
young
pulmonari
hypertens
patient
increas
ddimer
morpholog
confirm
attack
cell
viru
peripher
decreas
level
also
indic
viru
infect
caus
significantli
compromis
function
report
decreas
level
increas
ratio
group
cteph
patient
suggest
cellular
immun
dysfunct
ratio
imbal
cteph
patient
present
studi
whole
human
genom
microarray
gene
ontolog
go
analysi
employ
detect
target
symptomat
pulmonari
embol
pe
addit
flow
cytometri
perform
investig
chang
immun
cell
vte
patient
aim
valid
result
genom
analysi
base
find
relationship
immun
dysfunct
clinic
symptomat
vte
analyz
cpr
level
part
vte
inpati
determin
pe
inpati
control
randomli
select
cardiolog
depart
tongji
hospit
tongji
univers
pe
group
male
femal
mean
age
year
year
patient
acut
pe
cteph
pulmonari
arteri
pressur
mmhg
cteph
patient
control
group
patient
male
femal
mean
age
year
year
enrol
period
signific
differ
age
found
pe
patient
control
patient
p
malign
use
immunosuppres
autoimmun
diseas
exclud
patient
total
clinic
proven
vte
patient
ape
dvt
cteph
age
year
year
recruit
tongji
hospit
includ
male
femal
immunolog
paramet
patient
compar
detect
interv
normal
popul
diagnost
criteria
acut
pe
diagnosi
dvt
base
criteria
previous
report
criteria
cteph
develop
american
aha
use
diagnosi
present
studi
patient
mean
pulmonari
arteri
systol
pressur
mmhg
malign
use
immunosuppres
autoimmun
diseas
exclud
patient
patient
shanghai
china
present
studi
approv
ethic
committe
tongji
hospit
inform
consent
obtain
studi
total
ml
venou
edta
anticoagul
blood
obtain
patient
group
mononuclear
cell
isol
densiti
gradient
centrifug
red
blood
cell
lysi
buffer
qiagen
hilden
germani
use
isol
mononuclear
cell
total
rna
extract
mononuclear
cell
trizol
invitrogen
carlsbad
usa
follow
purif
rneasi
column
qiagen
treatment
dnase
perform
avoid
influenc
genom
dna
quantif
extract
rna
perform
nanodrop
spectrophotomet
nanodrop
technolog
cambridg
uk
agil
whole
human
genom
oligo
microarray
purchas
agil
usa
microarray
compos
spot
includ
gene
transcript
neg
control
spot
posit
control
spot
blank
spot
function
gene
microarray
known
patient
group
subject
microarray
analysi
indirect
approach
appli
mark
sampl
total
rna
revers
transcrib
doubl
strand
cdna
purif
vitro
amplif
perform
agil
low
rna
input
linear
amplif
kit
agil
pal
alto
usa
modifi
utp
aautp
utp
use
replac
utp
integr
aautp
interact
nh
ester
form
fluoresc
product
use
hybrid
integr
rate
fluoresc
determin
spectrophotomet
hybrid
mixtur
prepar
agil
oligonucleotid
microarray
situ
hybrid
plu
kit
ng
fluoresc
product
fragment
hybrid
conduct
human
wholegenom
oligochip
agil
technolog
h
rpm
hybrid
chip
wash
agil
gene
express
wash
buffer
accord
manufactur
instruct
origin
signal
obtain
agil
scanner
featur
extract
softwar
standard
origin
signal
carri
rma
standard
method
standard
signal
valu
use
screen
differenti
express
gene
spot
microarray
randomli
select
express
confirm
rtpcr
among
gene
differenti
express
gene
randomli
select
gene
hous
keep
gene
gapdh
subject
rtpcr
rel
express
express
express
target
gene
normal
gapdh
melt
curv
method
use
compar
differ
express
control
group
pe
group
result
rtpcr
consist
microarray
analysi
gene
ontolog
organ
gene
function
hierarch
categori
base
biolog
process
molecular
function
cellular
compon
fisher
exact
test
appli
represent
select
gene
go
biolog
categori
order
assess
signific
particular
categori
random
chanc
fals
discoveri
rate
fdr
estim
categori
resampl
fdr
defin
nk
refer
subtract
number
fisher
test
random
sampl
specifi
threshold
signific
go
pvalu
fdr
enrich
paramet
enrich
repres
degre
gene
express
signific
equat
enrich
follow
nfn
nfn
nf
number
signific
gene
within
particular
categori
n
total
number
gene
within
categori
nf
number
signific
gene
entir
microarray
n
number
gene
test
agil
featur
extract
softwar
use
collect
origin
data
microarray
follow
analysi
robust
multichip
averag
rma
gene
intens
data
pe
group
control
group
compar
test
calibr
stochast
varianc
model
differenti
express
gene
identifi
whole
genom
independentsampl
test
use
compar
mrna
level
sampl
pe
patient
control
statist
test
perform
use
spss
p
valu
consid
signific
test
test
equal
varianc
perform
varianc
equal
test
result
would
correct
sampl
collect
fast
venou
blood
ml
collect
morn
ad
et
tube
flow
cytometri
perform
detect
differenti
antigen
immun
cell
beckmancoult
epic
xlii
flow
cytomet
patient
detect
nk
cell
marker
detect
patient
crp
level
vte
patient
detect
scintil
turbidimetri
go
analysi
target
compromis
immun
function
cell
decreas
express
immun
receptor
complex
pe
patient
among
gene
relat
activ
chemotaxi
neutrophil
mrna
express
gene
significantli
upregul
pe
group
figur
pe
patient
mrna
express
mononuclear
cell
surfac
antigen
markedli
upregul
macrophag
activ
factor
also
significantli
upregul
addit
mrna
express
relat
fc
fragment
surfac
receptor
itgal
larg
increas
significantli
figur
mrna
express
remain
unchang
pe
group
mrna
express
well
receptor
complement
integrin
markedli
upregul
membran
attack
complex
compon
significantli
downregul
compar
control
group
figur
pe
group
mrna
express
ifn
regulatori
factor
tnf
markedli
upregul
mrna
express
significantli
downregul
compar
control
group
figur
pe
group
express
killer
lectinlik
receptor
klr
markedli
downregul
compar
control
group
mrna
express
also
markedli
downregul
figur
mrna
express
significantli
upregul
pe
group
figur
pe
group
mrna
express
cell
mediat
cellular
immun
protein
kinas
relat
transmembran
signal
transduct
protein
tyrosin
cell
surfac
antigen
especi
membran
surfac
immun
receptor
complex
cell
granzym
markedli
downregul
compar
control
group
figur
total
paramet
measur
pe
patient
abnorm
one
paramet
abnorm
express
decreas
increas
figur
aberr
express
decreas
increas
figur
abnorm
express
decreas
increas
figur
aberr
ratio
decreas
increas
figur
abnorm
nk
express
patient
decreas
increas
figur
aberr
express
patient
decreas
increas
figur
express
decreas
patient
express
decreas
patient
express
decreas
patient
figur
vte
patient
patient
receiv
crp
determin
crp
level
patient
higher
normal
rang
figur
go
analysi
genom
studi
target
decreas
immun
function
cell
immun
receptor
complex
pe
patient
suggest
occurr
pe
close
relat
immun
dysfunct
statist
analysi
reveal
mrna
express
gene
associ
innat
immun
cytokin
markedli
upregul
relat
cellular
immun
cell
nk
cell
significantli
downregul
addit
cytolog
experi
indic
paramet
relat
immun
function
abnorm
vte
patient
express
markedli
reduc
ratio
significantli
increas
number
cell
reduc
result
cytolog
examin
genom
analysi
consist
among
patient
vte
decreas
cell
reduc
cell
increas
ratio
find
indic
abil
cell
recogn
antigen
transmit
activ
signal
significantli
compromis
capabl
cell
kill
pathogen
infect
cell
decreas
compromis
cell
immun
function
often
identifi
patient
malign
use
immunosuppress
viral
infect
malnutrit
present
studi
none
patient
malign
treat
immunosuppress
therefor
pathogenesi
vte
might
close
relat
viral
infect
malnutrit
report
synthesi
releas
viruslik
microorgan
note
lymphocyt
electron
microscop
young
pulmonari
hypertens
patient
increas
ddimer
among
patient
vte
decreas
nk
cell
suggest
abil
nk
cell
kill
intracellular
pathogen
includ
viru
impair
express
b
lymphocyt
normal
hemopoiet
system
follicular
dendrit
cell
fdc
germin
center
express
detect
back
progenitor
b
cell
present
matur
b
lymphocyt
b
cell
differenti
plasma
cell
express
absent
involv
flux
b
lymphocyt
regul
activ
prolifer
b
cell
among
vte
patient
decreas
express
suggest
activ
prolifer
b
cell
compromis
vte
patient
express
separ
combinedli
downregul
ratio
abnorm
result
impli
occurr
vte
close
relat
immun
function
present
studi
cell
andor
cell
decreas
vte
patient
downregul
andor
found
patient
find
indic
symptomat
vte
associ
decreas
innat
immun
adapt
immun
patient
moreov
vte
patient
one
immun
dysfunct
among
vte
patient
normal
immun
function
two
patient
male
acut
pe
patient
femal
acut
pe
patient
receiv
genet
test
remain
one
patient
femal
patient
diagnos
cteph
underw
splenectomi
year
ago
patient
abnorm
immun
function
admiss
difficult
confirm
immun
function
becam
abnorm
howev
found
patient
downregul
develop
symptomat
vte
sequenti
among
vte
patient
patient
symptom
respiratori
infect
histori
respiratori
infect
recent
among
vte
patient
crp
measur
patient
increas
crp
impli
inflamm
relat
occurr
vte
respons
invas
foreign
pathogen
human
bodi
instantan
innat
immun
respons
occur
within
hour
infect
earli
innat
immun
respons
occur
hour
dvt
pe
often
occur
day
postop
coincid
infect
process
innat
adapt
immun
follow
period
vte
patient
includ
die
lost
follow
among
patient
receiv
follow
treat
warfarin
anticoagul
addit
immunolog
examin
detect
ddimer
also
carri
design
time
point
result
show
vte
patient
receiv
follow
increas
ddimer
level
year
warfarin
discontinu
immunolog
examin
detect
dd
dimer
show
normal
patient
symptomat
vte
relationship
vte
immun
dysfunct
found
nevertheless
patient
immun
dysfunct
develop
symptomat
vte
short
time
compromis
disorgan
immun
function
may
intern
caus
suscept
acquir
vte
infect
act
trigger
factor
acquir
vte
pathogen
invad
subject
immun
dysfunct
pathogen
complet
remov
immun
system
thu
patient
compromis
disorgan
immun
function
suscept
acquir
vte
